Mabwell(SH:688062) Xin Lang Cai Jing·2025-11-13 02:07Group 1 - The core point of the news is that Maiwei Biotech's stock price increased by 5.07% to 45.98 CNY per share, with a trading volume of 1.28 billion CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 183.74 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, is primarily engaged in the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales and 0.09% from services [1] Group 2 - Among the top ten circulating shareholders of Maiwei Biotech, E Fund's healthcare mixed fund (110023) entered the list in the third quarter, holding 3.1746 million shares, which is 1.55% of the circulating shares, with an estimated floating profit of approximately 7.0476 million CNY [2] - E Fund's healthcare mixed fund (110023) was established on January 28, 2011, with a current scale of 3.802 billion CNY, achieving a year-to-date return of 35.72% and a one-year return of 22.42%, ranking 2184 out of 8145 and 3130 out of 8059 respectively [2]